Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Chronic PancreatitisInsulin Dependent Diabetes
Interventions
DRUG

Hydroxychloroquine

Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.

DRUG

Placebo

Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER

collaborator

Stanford University

OTHER

lead

The Cleveland Clinic

OTHER

NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT | Biotech Hunter | Biotech Hunter